Nirmatrelvir

奈玛特韦

Report date: 2024/11/05 20:00:08
NME

Base Information

Drug NameNirmatrelvir
Drug Alias NamePF-07321332
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer As
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdBeximco PharmaPfizer Inc +[8] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A